Intra-Cellular Surges On First Phase III Schizophrenia Data
This article was originally published in Scrip
Intra-Cellular Therapies saw its share price climb 86.9% to close at a new peak of $48.79 on Sept. 16 after the company reported that ITI-007 showed a potentially differentiated safety profile relative to approved antipsychotic drugs in the first of two Phase III schizophrenia clinical trials.
You may also be interested in...
The unexpected failure of a Phase III trial of Intra-Cellular Therapies’ lead product ITI-007 sent shares in the company down by more than 63%.
Development of gosuranemab in tauopathies will end after a Phase II progressive supranuclear palsy trial failure, but a Phase II Alzheimer’s study of the drug licensed from BMS is ongoing.
Public Company Edition: The last biopharma initial public offering in the US was on 11 November, but follow-on and other offerings are generating hundreds of millions of dollars. Among RNA drug developers, Ionis issued more than $500m in new debt, while Arrowhead raised $266.8m.